Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline
BOSTON--(BUSINESS WIRE)--Jun 21, 2022--
Source: kulr8.com
Mariesa Kemble News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mariesa Kemble. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mariesa Kemble Today - Breaking & Trending Today
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
Source: prnewswire.com
POGO Automatic One-Step™ Blood Glucose Monitor Now Available for People with Diabetes in the United States
/PRNewswire/ -- Intuity Medical, Inc., a commercial-stage medical technology and digital health company focused on making life with diabetes easier, announced...
Source: prnewswire.com
Reportable, Inc.: Cofactor Genomics Commences First Predictive Immune Modeling Clinical Trial to Bridge Precision Medicine Gap for Immunotherapy
(0) San Francisco, California--(Newsfile Corp. - April 13, 2021) - Cofactor Genomics, the company bridging the precision medicine gap, today announced commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company's patented approach to generating multidimensional immune biomarkers. Fifteen hospitals and healthcare networks, including Mayo Clinic, MultiCare Institute for Research and Innovation, and Revive Research Institute, are currently enrolling in the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies)...
Source: finanznachrichten.de